Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07543172 · ClinicalTrials.gov registry record · Phase 2
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT07543172 is a Phase 2 study that has not yet begun recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 29 participants.
The verdict
NCT07543172, a Phase 2 study, has not yet begun recruiting, sponsored by Roswell Park Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase II trial tests how well giving CIMAvax-EGF with KRAS G12C inhibitor (sotorasib or adagrasib) for the treatment of patients with KRAS G12C mutated non small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Vaccines, such as CIMAvax-EGF, made from specific peptides or antigens may help the body build an effective immune response to kill tumor cells. Sotorasib and adagrasibare in a class of medications called kinase inhibitors. They work by blocking the signals that cause tumor cells to multiply. This helps to stop the spread of tumor cells. Giving CIMAvax-EGF with a KRAS G12C inhibitor may be effective for treating advanced, KRAS G12C mutated non small cell lung cancer.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Adagrasib
- BIOLOGICAL Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07543172
The ClinicalTrials.gov registry entry for NCT07543172 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07543172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07543172 about?
NCT07543172 is a clinical study titled "CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer". This phase II trial tests how well giving CIMAvax-EGF with KRAS G12C inhibitor (sotorasib or adagrasib) for the treatment of patients with KRAS G12C mutated non small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanc...
What is the current status of trial NCT07543172?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2026-06-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07543172?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Adagrasib (DRUG), Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07543172?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.